Braveheart Bio (BRVE)
Developing BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy.
$26.77
At close+0.49 (+1.86%)
Something off on this page? Send us feedback.
Next report
Dec 2, 2026
estimated · in 90 days
EPS estimate
$2.69
Revenue estimate
—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | $2.69 | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2, 2026 | $2.69 | — | — | — | — | — | — |